Logiscreen

Regeneron Pharmaceuticals Inc

$635.45
Market Cap 67.18B
ROE 14.3%
Gross Margin 81.4%
Debt/Equity 0.1
Current Ratio 3.6
Revenue QoQ 19.0%
EPS QoQ -0.1%
F-Score 4

About

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
15.03
vs median 31.50
P/B
2.12
vs median 2.17
ROE
0.14
vs median 0.09

Lower quality - review fundamentals carefully

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics